Anticipate generic drug launch
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Chromatographic purification process|
|Abstract:||This invention relates to a new chromatographic process for purifying fermentation products, particularly the antibiotic LY146032, from fermentation broths by use of a reverse phase non-functional resin. In the process of this invention the resin is loaded with the compound in the aqueous phase, the water then is removed from the resin and the resin converted to the organic phase for the resolution step. This process is applicable to purifying compounds which are adsorbed on reverse phase non-functional resins.|
|Inventor(s):||Baker; Patrick J. (Greenwood, IN)|
|Assignee:||Eli Lilly and Company (Indianapolis, IN)|
|Filing Date:||Dec 03, 1987|
|Claims:||1. A process for purifying fermentation products which comprises: |
a. contacting an aqueous solution of a fermentation product with a non-functionalized macroporous copolymer of styrene and divinylbenzene in aqueous phase;
b. physically removing the water from the charged resin;
c. rewetting the charged resin with a polar organic solvent;
d. washing the resin with a polar organic solvent that is the same as or different than the polar organic solvent used in step (C) to remove non-uv impurities;
e. eluting the fermentation product from the non-functional resin by increasing the polarity of the solvent; and
f. recovering the fermentation product.
2. The process of claim 1 wherein the fermentation product is a lipopeptide.
3. The process of claim 2 wherein the fermentation product is LY146032.
4. The process of claim 2 wherein the fermentation product is Echinocandin B.
5. The process of claim 1 wherein the fermentation product is a glycopeptide.
6. The process of claim 4 wherein the fermentation product is vancomycin.
7. The process of claim 1 wherein the resin is Diaion HP-20.
8. The process of claim 1 wherein the resin is amberlite XAD-4.
9. The process of claim 1 wherein the polar organic solvent is acetonitrile.
10. The process of claim 1 wherein the fermentation product is eluted from the non functionalized macroporous copolymer of styrene and divinylbenzene with acetonitrile containing from about 5% to about 60% water.
11. The process of claim 9 wherein the fermentation product is eluted from the non-functionalized macroporous copolymer of styrene and divinylbenzene with acetonitrile containing from about 10% to about 20% water.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.